24/7 Market News Snapshot 26 Jun 2024 – DiaMedica Therapeutics Inc. Common Stock (NASDAQ: DMAC)

June 26, 2024 7:18

Press Release

DENVER, Colo., 26 June, 2024 (247marketnews.com) – (Nasdaq:DMAC) are discussed in this article.
DiaMedica Therapeutics Inc. Common Stock (DMAC) has demonstrated a remarkable 25.62% surge in trading, reaching $2.840 from an opening price of $2.58, with substantial trading volume. The market response indicates a bullish trend, reflecting investor confidence in the company’s future outlook. This positive momentum may stem from potential growth catalysts and heightened market interest, presenting opportunities for traders and prompting investors to conduct thorough due diligence for informed decision-making.

In a strategic move to bolster its financial position, DiaMedica Therapeutics Inc. (Nasdaq:DMAC) has successfully concluded definitive agreements for a private placement offering, garnering an estimated $11.8 million in gross proceeds. The offering entails issuing 4,720,000 common shares at $2.50 per share to accredited investors, with the transaction slated for closure around June 28, 2024, subject to customary conditions. The infusion of capital aims to support the advancement of the company’s innovative therapies, particularly the pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke treatment and foray into addressing preeclampsia, ultimately extending DiaMedica’s financial runway into the third quarter of 2026.

Additionally, DiaMedica’s strategic diversification into preeclampsia clinical trials underscores its commitment to addressing unmet medical needs. The participation of non-management related parties in the private placement reflects a collaborative effort towards progress in treating ischemic diseases. These developments underline DiaMedica’s dedication to enhancing patient care and pioneering therapeutic solutions for critical medical conditions.

For further information on DiaMedica Therapeutics Inc. and its groundbreaking advancements in developing DM199 (rinvecalinase alfa) for acute ischemic stroke and preeclampsia treatments, kindly visit the company’s official website. This press release contains forward-looking statements, and readers are advised to refer to DiaMedica’s regulatory filings for comprehensive insights into potential factors influencing the Company’s future performance.

Stay informed about DiaMedica’s transformative contributions to the field of ischemic diseases as they advance innovative treatment approaches. Please be aware that the private placement of common shares is not registered under the U.S. Securities Act of 1933 or relevant state securities laws.

Source: Business Wire

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.